mycobacterium avium-intracellulare infection/protease

Линкът е запазен в клипборда

Изберете тип сортиране

8 резултата

[Effects of secretory leukocyte protease inhibitor on the production of some cytokines and nitric oxide by murine peritoneal macrophages in response to lipopolysaccharide stimulation and M. avium complex infection].

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Secretory leukocyte protease inhibitor (SLPI), a serine protease inhibitor abundantly found in mucous secretions of lung, is thought to serve as an important protective component in the secretory fluids at sites of degenerative and inflammatory diseases. In this study, we examined the effects of

The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

OBJECTIVE To optimize the conditions for determining Caco-2 permeation of HIV protease inhibitors and other lipophilic compounds, and to compare cyclic urea HIV protease inhibitors with marketed compounds. METHODS Absorptive and secretory Caco-2 membrane permeation studies were performed with HIV

Imaging of Mycobacterium avium-intracellulare infection in AIDS patients on highly active antiretroviral therapy: reversal syndrome.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

OBJECTIVE We recently encountered six patients with AIDS and an unusual complication of disseminated infection with Mycobacterium avium-intracellulare, which developed after the initiation of highly active antiretroviral therapy, including protease inhibitors and two new nucleoside analogues. Each

[Disseminated infection with Mycobacterium avium complex (MAC) in HIV infection].

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Disseminated MAC-infection is one of the most frequent opportunistic infections occurring in HIV-infected patients. Severely immunocompromised patients with CD4-counts < 50/microliter are at greatest risk for the disease. Survival of untreated infection is very poor (5 to 6 months). With

Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Because most HIV-infected patients die of diseases caused by opportunistic pathogens, the prevention of these infections is an important clinical issue. Cost-containment in the healthcare system is a subject of high priority in public debate. Methods to determine cost-effectiveness of different

Risk-benefit assessment of therapies for Mycobacterium avium complex infections.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Mycobacterium avium complex (MAC) is an important pathogen that can cause chronic lung disease in immunocompetent patients and disseminated disease in patients with the acquired immunodeficiency syndrome (AIDS). Treatment of MAC with antituberculosis drugs was unsatisfactory, but the introduction of

Disseminated Mycobacterium avium complex infection: implications of recent clinical trials on prophylaxis and treatment.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

A number of additional questions regarding prophylaxis and treatment of MAC disease remain. Should MAC prophylaxis be stopped for patients whose CD4 counts increase above the threshold of risk after treatment with highly active antiretroviral therapy? Are the CD4 cells recovered in the latter

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND The efficacy of triple-drug antiretroviral regimens in the treatment of patients infected with HIV has been established in several randomized clinical trials. However, the effectiveness of these new regimens in patient populations outside clinical trials remain unproven. This study

Присъединете се към нашата
страница във facebook

Herbal & Natural Medicine

Най-пълната база данни за лечебни билки, подкрепена от науката

Работи на 55 езика
Билкови лекове, подкрепени от науката
Разпознаване на билки по изображение
Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
Прочетете научни публикации, свързани с вашето търсене
Търсете лечебни билки по техните ефекти
Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания